DAFTAR PUSTAKA

1. Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D. 1991. Polycystic Ovarian Desease : contribution of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertile Steril 55: 1062-1068. 2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. 2006. Criteria for Defining Polycystic Ovarian Syndrome as a Predominantly Hyperandrogenic Syndrome. Journal of Clinical Endrocinology and Metabolism 91: 114237-4245. 3. Barbieri RL. 2007. Polycystic Ovarian Syndrome section 16, chap 5. In: Dc Dale, DD Federman. ACP Medicine eds. WebMD. New York. 4. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. 2005. Phenotipic Spectrum of Polycystic Ovarian Syndrome: Clinical and Biochemical Characterization of the Three major Clinical Subgroups. Fertile Steril 83: 1717-1723. 5. Cibula D, Cifkova R, Fanta M. 2000. Increased Risk of Non-insulin Dependent Diabetes Melitus, Arterial Hipertension, and Coronary artery Disease in Perimanopausal Women with a History of Polycystic Ovarian Syndrome. Hum Reprod 15: 785-9. 6. Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B, Jagasia DH. 2005. Screening Women with Polycystic Ovarian Syndrome for Metabolic Syndrome. The American College of Obstetricians and Gynecologists 106: 131-7. 7. Douche T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Nagata Y. 1999. Serum Androgen Levels and Muscle Mass in Women with Polycystic Ovarian Syndrome. Obstet Gynecol 94: 337-40. 8. Dunaif A. 1997. Insulin Resistance and The Polycystic Ovarian Syndrome: Mechanism and Implications for Pathogenesis. Endocrine Review 18: 774-800. 9. Ehrmann DA. 2005. Review Article: Polycystic Ovarian Syndrome. The New England Journal of Medicine 352(12): 1223-1236. 10. ESHRE/ASRM. 2004 Revised 2003. Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovarian Syndrome. Fertile Steril 81: 19-25.

11. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. 2003. Incidence and Treatment of Metabolic Syndrome in Newly Reffered Women with confirm Polycystic Ovarian Syndrome. Metabolism 52: 908-915. 12. Hass DA. 2003. Effects of Metformin on Body Mass Index, Menstrual Cyclicity, and Ovulation Induction in Women with Polycystic Ovarian Syndrome. Fertility and Sterility 79(3): 496-481. 13. Hunter MH, Sterret JJ. 2000. Polycystic Ovarian Syndrome: Its not Just Infertility. American Family Physician 62: 5. 14. Kandarakis ED, Spina G, Kouli C. 2001. Increased Endothelin-1 Levels in Women with Polycystic Ovarian Syndrome and The Beneficial Effect of Metformin Therapy. J Clin Endocrinol Metabolism 86: 4666-73. 15. Sari RF. 2003. Sindrom Ovarium Polikistik: diam-diam menghanyutkan. Polycystic Ovarian Syndrome Care Community. 16. Speroff L, Fritz MA. 2005. Anovulation and The Polycystic Ovary p: 465-496. Clinical Gynecology Endrocrinology and Infertility. 7th ed. Lippincott Williams and Wlikins. 17. Williamson K, Gunn AJ, Johnson N, Milsom SR. 2001. The Impact of Ethnicity on The Presentation of Polycystic Ovarian Syndrome. Aust NZJ Obstetric Gynecol 41:202-206.